Please provide your email address to receive an email when new articles are posted on . The phase 2 DR:EAM clinical trial did not meet the endpoint of the percentage of patients with a two-step or ...
According to the phase II/III DIAMOND trial, there was early evidence of efficacy for OCS-01 eye drops in patients with diabetic macular edema (DME) compared with sham. The findings were reported at ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...
OcuTerra Therapeutics’ investigational eye drops failed to improve disease severity or progression in a phase 2 diabetic retinopathy trial, prompting the Boston-based biotech to look at strategic ...
CAMBRIDGE, England & NOTTINGHAM, England--(BUSINESS WIRE)--Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases ...
Please provide your email address to receive an email when new articles are posted on . EXN407 met primary endpoints of safety and tolerability and also demonstrated decreases in vascular leakage and ...
ZUG, Switzerland, and BOSTON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, ...
Fundus photography involves taking a photo of the back of the eye to detect signs of diabetic retinopathy. It is also possible to capture an image of the retina using a smartphone. Diabetic ...
Diabetic eye disease is the leading cause of blindness among people ages 40 to 60. The longer you have diabetes, the greater your likelihood of developing vision problems increases. Keeping blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results